Researcher, Cell Laboratory, Institute of Biological Products Verification, China Institute of Food and Drug Verification, is mainly engaged in quality control of biological products. In recent years, it has undertaken or participated in a number of national projects, covering the fields of cell matrix, immunocytotherapy, tissue engineering cells and stem cells, focusing on cell quality control methods and quality standards. He is currently a national expert in new drug review, member of the 11th National Pharmacopoeia, member of the National and Beijing Stem Cell Clinical Research Committee, etc.

Xiao Jieqiong has ten years of experience in the field of biopharmaceuticals. She is currently the technical director of Gibco cell culture product line in the Bio-industry Department of ThermoFisher Scientific. She leads the Gibco cell culture technology team to provide solutions in the fields of cell therapy, gene therapy, antibodies and vaccines that meet the requirements of technology and regulations. In 2012, he received a master's degree in cell biology from Xiamen University and participated in the process development of recombinant HPV vaccine and the preparation of various HPV pseudoviruses.

Dr. Zhang is the co-founder, president and CEO of AEON(Beijing) a joint venture between Eureka Therapeutics Inc. and Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Prior to the establishment of Yiang Biology, Dr. Zhang Yu served as assistant president and senior strategic planning expert of Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Dr. Zhang received a bachelor's and master's degree in biomedical engineering from Beijing University of Aeronautics and Astronautics, and a doctor's degree in stem cell and regenerative medicine from Heinrich-Heine-Universit t Dyusseldorf University in Heinrich, Germany. During his stay in Germany, he served as a director of the Rhine Forum in Germany, a lecturer at the Rhine University of Science and Technology in Bonn, Germany, a visiting scholar at the Helmholtz Center of the German Space Agency and the University of Palermo in Italy. Dr. Zhang is a member of the German Stem Cell Society, the Chinese Society of Cell Biology and a reviewer of Current Stem Cell Research & Therapy magazines. Selected 131 talents plan, the first batch of Tianjin Green Card winners.

Dr. Zhang is the co-founder, president and CEO of AEON(Beijing) a joint venture between Eureka Therapeutics Inc. and Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Prior to the establishment of Yiang Biology, Dr. Zhang Yu served as assistant president and senior strategic planning expert of Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Dr. Zhang received a bachelor's and master's degree in biomedical engineering from Beijing University of Aeronautics and Astronautics, and a doctor's degree in stem cell and regenerative medicine from Heinrich-Heine-Universit t Dyusseldorf University in Heinrich, Germany. During his stay in Germany, he served as a director of the Rhine Forum in Germany, a lecturer at the Rhine University of Science and Technology in Bonn, Germany, a visiting scholar at the Helmholtz Center of the German Space Agency and the University of Palermo in Italy. Dr. Zhang is a member of the German Stem Cell Society, the Chinese Society of Cell Biology and a reviewer of Current Stem Cell Research & Therapy magazines. Selected 131 talents plan, the first batch of Tianjin Green Card winners.

Dr. Victor Li has 25 years experience in biopharmaceutical industry and 4 years experience in clinical medicine. He founded his first biotechnology company and successfully transferred the company after completing phase I/II clinical trials of two vaccine products. As co-founder and director of several biotechnology companies in Singapore, such as Lion TCR, BioCheetah and ImmuNOA, SCG Cell and BioSyngen, they are start-up biotechnology companies separated from Singapore A*Star and Munich University of Technology (TUM). Their business is focused on immune T cell cancer treatment and concomitant diagnosis. Prior to that, he worked at PricewaterhouseCoopers in management consulting for the medical biotechnology industry and Ciba-Geigy Pharmaceutical.

Li Runrun, graduated from the School of Pharmacy, Peking University Medical Department, master of chemical biology, and dual degree in economics, Beida National Development Research Institute. He is currently working in the Investment Promotion Center of the Management Committee of Taizhou Pharmaceutical Hi-tech Industrial Park and serves as Deputy Director-General of the Third Bureau of the Investment Promotion Center.

In the mid-1990s, Dr. Lai Shoupeng carried out postdoctoral research on cancer immunotherapy in Steven Rosenburg Laboratory, Director of Surgery, National Cancer Institute of the United States. After entering the biomedical industry, he has been engaged in research and development of new biological drugs for more than 20 years. He has accumulated rich experience in biopharmaceutical technology development, GMP production and project management. In 2014, Nanjing leadsbiolabs Co., Ltd. was co-founded, focusing on the development of new anti-cancer drugs for immunotherapy.

Ten years of pre-clinical CMC development experience in biotechnology has rich experience in process development and scale-up production. Manage and participate in 8 biopharmaceutical projects. As the head of the first project, he has completed the development of the commissioned new biological drug project, KLT-1101, a national class of anti-cancer, whole blood picture recovery drug, and completed its complex process and quality control standards. He has successfully passed on-site verification and obtained CFDA clinical experimental approval in a very short period of time. Since 2017, a clinical CMC development platform for Car-T cell therapeutic transfection plasmids has been established, and the CMC Development Research of plasmid part in the first Car-T declaration of CFDA has been completed and declared, and the clinical trial approval has been successfully obtained. Over the past years, project management has accumulated rich pre-clinical CMC development experience.